|
Market Closed -
Nasdaq
21:00:00 23/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 26.38 USD | -5.04% |
|
+0.92% | -9.16% |
| 09-16 | Arcutis Biotherapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 01:50 PM | |
| 08-24 | Oruka Therapeutics Names Chief Commercial Officer | MT |
| Market Cap | 3.32B 2.91B 2.74B 2.5B 4.67B 318B 4.71B 32.86B 12.74B 162B 12.45B 12.18B 525B | P/E 2026 * |
65.6x | P/E 2027 * | 20.4x |
|---|---|---|---|---|---|
| Enterprise Value | 3.03B 2.66B 2.5B 2.28B 4.27B 290B 4.3B 30B 11.63B 148B 11.37B 11.12B 479B | EV / Sales 2026 * |
5.63x | EV / Sales 2027 * | 3.9x |
| Free-Float |
98.23% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| ARQT | Delayed | |
CBOE
| ARQT | Real-time |
Last Transcript: Arcutis Biotherapeutics, Inc.
| 1 day | -5.04% | ||
| 1 week | +0.92% | ||
| Current month | +10.05% | ||
| 1 month | +5.18% | ||
| 3 months | +0.42% | ||
| 6 months | +18.35% | ||
| Current year | -9.16% |
| 1 week | 25.13 |  | 28.29 |
| 1 month | 23.1 | | 28.29 |
| Current year | 19.3 | | 30.75 |
| 1 year | 16.57 | | 31.77 |
| 3 years | 1.76 | | 31.77 |
| 5 years | 1.76 | | 31.77 |
| 10 years | 1.76 | | 40.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
Todd Watanabe
CEO | Chief Executive Officer | 58 | 31/03/2017 |
| Corporate Officer/Principal | 71 | 02/12/2025 | |
Latha Vairavan
DFI | Director of Finance/CFO | - | 14/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Patrick Heron
CHM | Chairman | 55 | 30/11/2019 |
Todd Watanabe
BRD | Director/Board Member | 58 | 31/12/2015 |
Howard Welgus
BRD | Director/Board Member | 74 | 31/07/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 16/09/26 | Sell | General Counsel | -3,674 | 0.0029% | ||
| 15/09/26 | Exercice | Director | 12,922 | 0.0103% | ||
| 08/09/26 | Sell | General Counsel | -9,989 | 0.0079% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.04% | +0.92% | +49.89% | +390.33% | 3.49B | |
| -0.26% | +3.51% | +41.19% | -2.79% | 80.27B | |
| -0.25% | +25.06% | +606.13% | +82.13% | 72.88B | |
| -0.19% | +0.76% | -9.34% | -29.28% | 61.51B | |
| -1.80% | -3.05% | -14.24% | +26.38% | 47.39B | |
| -0.89% | +2.67% | +3.52% | +157.67% | 46.58B | |
| +0.96% | +5.33% | +63.33% | -11.70% | 33.3B | |
| -1.80% | -0.09% | +47.43% | +114.53% | 25.73B | |
| -2.80% | +4.52% | +5.73% | +157.69% | 22.88B | |
| -1.92% | +0.05% | +57.90% | +100.00% | 15.82B | |
| Average | -1.49% | +4.94% | +85.15% | +98.50% | 40.99B | |
| Weighted average by Cap. | -0.90% | +6.74% | +124.31% | +52.86% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 537M 472M 443M 405M 757M 51.47B 763M 5.32B 2.06B 26.24B 2.02B 1.97B 85.08B | 687M 603M 567M 518M 968M 65.8B 975M 6.81B 2.64B 33.55B 2.58B 2.52B 109B |
| Net income | 53.27M 46.75M 43.95M 40.18M 75.08M 5.1B 75.64M 528M 205M 2.6B 200M 196M 8.43B | 173M 152M 143M 131M 244M 16.59B 246M 1.72B 665M 8.46B 650M 636M 27.42B |
| Net Debt | -288M -253M -238M -218M -407M -27.63B -410M -2.86B -1.11B -14.08B -1.08B -1.06B -45.67B | -638M -560M -526M -481M -899M -61.09B -906M -6.32B -2.45B -31.15B -2.39B -2.34B -101B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/09/26 | US$26.38 | -5.04% | 2,512,178 |
| 22/09/26 | US$27.78 | +7.01% | 2,857,941 |
| 21/09/26 | US$25.96 | +2.29% | 1,888,258 |
| 18/09/26 | US$25.38 | -4.08% | 19,137,072 |
| 17/09/26 | US$26.46 | +1.22% | 5,862,795 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ARQT Stock
Select your edition
All financial news and data tailored to specific country editions
